These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 10843152)

  • 1. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
    Downs RW; Bell NH; Ettinger MP; Walsh BW; Favus MJ; Mako B; Wang L; Smith ME; Gormley GJ; Melton ME
    J Clin Endocrinol Metab; 2000 May; 85(5):1783-8. PubMed ID: 10843152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis.
    Yan Y; Wang W; Zhu H; Li M; Liu J; Luo B; Xie H; Zhang G; Li F
    J Bone Miner Metab; 2009; 27(4):471-8. PubMed ID: 19343272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
    Adami S; Passeri M; Ortolani S; Broggini M; Carratelli L; Caruso I; Gandolini G; Gnessi L; Laurenzi M; Lombardi A
    Bone; 1995 Oct; 17(4):383-90. PubMed ID: 8573412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women.
    Wasnich RD; Ross PD; Thompson DE; Cizza G; Yates AJ
    Osteoporos Int; 1999; 9(5):455-60. PubMed ID: 10550466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
    Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
    J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis.
    Sanad Z; Ellakwa H; Desouky B
    Climacteric; 2011 Jun; 14(3):369-77. PubMed ID: 21254911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin.
    Adami S; Baroni MC; Broggini M; Carratelli L; Caruso I; Gnessi L; Laurenzi M; Lombardi A; Norbiato G; Ortolani S
    Osteoporos Int; 1993; 3 Suppl 3():S21-7. PubMed ID: 8298199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
    Body JJ; Gaich GA; Scheele WH; Kulkarni PM; Miller PD; Peretz A; Dore RK; Correa-Rotter R; Papaioannou A; Cumming DC; Hodsman AB
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4528-35. PubMed ID: 12364430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group.
    Ravn P; Weiss SR; Rodriguez-Portales JA; McClung MR; Wasnich RD; Gilchrist NL; Sambrook P; Fogelman I; Krupa D; Yates AJ; Daifotis A; Fuleihan GE
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1492-7. PubMed ID: 10770187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
    Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate.
    Watts NB; Jenkins DK; Visor JM; Casal DC; Geusens P
    Osteoporos Int; 2001; 12(4):279-88. PubMed ID: 11420777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.